Added to YB: 2025-03-04
Pitch date: 2025-03-01
ALLK [bullish]
Allakos Inc.
+17.12%
current return
Author Info
Triple S is a professional special situations investor who shares ideas in their newsletter. Sign up for the newsletter.
Company Info
Allakos Inc., a clinical stage biotechnology company, engages in the development of therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
Market Cap
$29.7M
Pitch Price
$0.28
Price Target
0.56 (+70%)
Dividend
N/A
EV/EBITDA
0.29
P/E
-0.41
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
The Curious Case of Allakos
ALLK: Trading below liquidation value at $0.28/share. $81M cash, $1B+ NOLs. Q2 2025 cash $35-40M post-restructuring. Activist Kevin Tang owns 9.7%. Potential NOL monetization (100%+ upside) or liquidation (neutral). Similar to LOGC deal. Risk/reward skews long.
Read full article (2 min)